
Incyte
INCY · NASDAQ · Biotechnology
Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time
- Market cap
- $24,6 bn
- Div. yield
- —
- Year to date
- +22,5%
Ratio score
based on 9 metrics as of 16.11.2026 ·
Verdict by our methodology based on current metrics. Not an investment recommendation.
Key metrics
3 ✓ · 2 — · 4 ✕ · 1 n/a · hover over a row or tap it to see the trend
All metrics
| Metric | Value | 5-year median | Industry median |
|---|---|---|---|
| P/E TTM | 61,1 | 21,2 | 42,1 |
| Forward P/E | 15,5 | — | 18,7 |
| PEG | 4,2 | — | 4,1 |
| P/S | 4,1 | 3,8 | 6,6 |
| EV/EBITDA | 32,7 | 19,8 | 28,2 |
| P/FCF | 12,8 | — | 26,0 |
| P/B | 4,4 | 3,6 | 9,8 |
Industry median — across 6 profitable companies in “Biotechnology” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.
Price chart
Compare with
Choose a stock
Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.
Analysts
Ratings, 35 analysts
- Buy
- 19
- Hold
- 16
- Sell
- 0
Beat the EPS forecast in 3 of the last 4 quarters
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| Q3 2026 | −3,93 | −3,60 | Up +8,3% |
| Q2 2026 | 2,14 | 3,09 | Up +44,1% |
| Q1 2026 | 1,40 | 1,81 | Up +29,4% |
| Q4 2025 | 1,97 | 1,80 | Down −8,5% |
Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.
Financials in charts
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,56 bn | 1,67 bn | 1,27 bn | 1,51 bn | 1,37 bn | 1,22 bn | 1,05 bn | 1,18 bn | 1,14 bn | 1,04 bn | 881 m | 1,01 bn |
| EPS | −3,86 | 2,81 | 1,47 | 1,46 | 2,11 | 2,04 | 0,80 | 0,95 | 0,54 | −2,04 | 0,75 | 0,89 |
| Margin | −50,4% | 35,0% | 23,8% | 19,9% | 31,1% | 33,3% | 15,0% | 17,1% | 9,4% | −42,6% | 19,2% | 19,8% |
| FCF | −675 m | 508 m | 369 m | 543 m | 559 m | 44,7 m | 266 m | 381 m | 311 m | −576 m | 219 m | 148 m |
From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.
Owners
Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.
Insider trades over 12 months
Over 12 months: no purchases, sales $65,8 m.
| Name | Amount | Shares | Price |
|---|---|---|---|
| stein steven h6 Nov 2026 · sale | $5,81 m | 48 576 | $119,66 |
| stein steven h6 Nov 2026 · sale | $8,81 m | 73 969 | $119,12 |
| stein steven h6 Nov 2026 · sale | $7,13 m | 60 270 | $118,27 |
| stein steven h6 Nov 2026 · sale | $2,62 m | 22 336 | $117,15 |
| stein steven h6 Nov 2026 · sale | $4,07 m | 35 042 | $116,06 |
| tray thomas3 Nov 2026 · sale | $72 566 | 610 | $118,96 |
| cagnoni pablo j15 Sep 2026 · sale | $1,69 m | 13 985 | $120,49 |
| cagnoni pablo j15 Sep 2026 · sale | $1,11 m | 9 233 | $120,50 |
| cagnoni pablo j19 Aug 2026 · sale | $1,36 m | 10 801 | $125,56 |
| cagnoni pablo j12 Aug 2026 · sale | $1,30 m | 10 803 | $120,04 |
| mayes patrick a5 Aug 2026 · sale | $273 646 | 2 207 | $123,99 |
| cagnoni pablo j5 Aug 2026 · sale | $1,31 m | 10 640 | $122,69 |
| mayes patrick a3 Aug 2026 · sale | $729 204 | 6 055 | $120,43 |
| mayes patrick a31 Jul 2026 · sale | $273 807 | 2 293 | $119,41 |
| mayes patrick a31 Jul 2026 · sale | $39 671 | 326 | $121,69 |
SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.
About the company
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- US
- IPO date
- 6 Dec 1993
- Website
- www.incyte.com
Company description, revenue by segment and region, and the CEO will come later.
Earnings
- Next report
- date not announced
An AI summary of the earnings call will come later.
Peers
| Company | Price | ||||
|---|---|---|---|---|---|
BIIBBiogen | $251,65 | 31★★★★★★★would not consider | 107,8 | +2,3% | 3,4% |
MRNAModerna | $215,27 | 22★★★★★★would not consider | — | +13,1% | −110,5% |
REGNRegeneron Pharmaceuticals | $952,40 | 67★★★★★★★★★would watch | 20,5 | +18,6% | 28,5% |
VRTXVertex Pharmaceuticals | $537,79 | 72★★★★★★★★★would consider | 33,7 | +10,5% | 30,7% |
GILDGilead Sciences | $167,58 | 25★★★★★★★would not consider | — | +6,5% | −12,5% |
Ratio — a score by our methodology, not an investment recommendation.




